Comparing two drug combos for a rare type of lymphoma
Part of Cancer clinical trials.
This trial tests whether a new combination of chemotherapy drugs (P-GEMD) works better than the standard combination (P-Gemox) for people with certain types of natural killer/T-cell lymphoma (a rare blood cancer). It's designed for newly diagnosed or advanced-stage patients who haven't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a specific type of lymphoma (early-stage non-nasal or advanced natural killer/T-cell lymphoma).
- You must have at least one tumor that can be measured on a scan (like a lymph node bigger than 1.5 cm or a spot in an organ bigger than 1 cm).
- Your overall health and daily activity level must be good (able to take care of yourself, up and about more than half the day).
- Your blood counts (white cells, platelets, hemoglobin) must be high enough to safely receive chemotherapy.
- Your liver and kidney function must be within acceptable limits based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This study tests a new combination of three drugs (Golidocitinib, Pegaspargase, and a PD-1 antibody) as the first treatment for people with a rare type of lymphoma called ENKTL. It aims to see if these drugs together can shrink tumors and improve outcomes.
This study tests a new combination of three drugs (selinexor, an anti-PD-1 antibody, and a chemotherapy regimen called P-GemOx) for people with NKT-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination works better than current options.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
This trial tests a new drug combined with chemotherapy for patients whose T-cell lymphoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink tumors and improve outcomes.
Hear when a new NK-T-Cell Lymphoma, Extranodal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.